Abstract:The continuous emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with increased transmissibility and profound immune-escape capacity makes it an urgent need to develop broad-spectrum therapeutics. Nanobodies have recently attracted extensive attentions due to their excellent biochemical and binding properties. Here, we report two high-affinity nanobodies (Nb-015 and Nb-021) that target non-overlapping epitopes in SARS-CoV-2 S-RBD. Both nanobodies could efficiently neutralize diverse viruses of SARS-CoV-2. The neutralizing mechanisms for the two nanobodies are further delineated by high-resolution nanobody/S-RBD complex structures. In addition, an Fc-based tetravalent nanobody format is constructed by combining Nb-015 and Nb-021. The resultant nanobody conjugate, designated as Nb-X2-Fc, exhibits significantly enhanced breadth and potency against all-tested SARS-CoV-2 variants, including Omicron sub-lineages. These data demonstrate that Nb-X2-Fc could serve as an effective drug candidate for the treatment of SARS-CoV-2 infection, deserving further in-vivo evaluations in the future. The pandemic of SARS-CoV-2 has led to a severe public health crisis. In view of the wide clinical-applications of antibody drugs, it has always been a research focus to identify new antibodies and/or nanobodies with anti-viral neutralizing activity. In this study, we identified two neutralizing nanobodies (Nb-015 and Nb-021) that target non-overlapping epitopes in SARS-CoV-2 S-RBD with high affinity. Both nanobodies could broadly neutralize diverse SARS-CoV-2 variants. Furthermore, we revealed two distinct neutralization mechanisms of Nb-015 and Nb-021 by high-resolution nanobody/S-RBD complex structures. Eventually, we engineered a bispecific nanobody conjugate which exhibits excellent inhibitory activity against SARS-CoV-2, including the original strain and the VOI and VOC variants. We believe that the nanobody conjugate identified in this study could serve as an effective anti-viral drug reserve for potential treatment of COVID-19.

Identification and application of a pair of noncompeting monoclonal antibodies broadly binding to the nucleocapsid proteins of SARS-CoV-2 variants including Omicron

Monoclonal Antibodies against Nucleocapsid Protein of SARS-CoV-2 Variants for Detection of COVID-19

Potential of Antibody Pair Targeting Conserved Antigenic Sites in Diagnosis of SARS-CoV-2 Variants Infection

Screening and identification of B cell epitope of the nucleocapsid protein in SARS-CoV-2 using the monoclonal antibodies

Characterization of monoclonal antibodies targeting SARS-CoV-2 spike glycoprotein: Reactivity against Delta and Omicron BA. 1 variants

High-throughput detection of neutralizing antibodies to SARS-CoV-2 variants using flow cytometry

Proteomics Platform Reveals Broad-Spectrum Nanobodies for SARS-CoV-2 Variant Neutralization

Production of a Monoclonal Antibody to the Nucleocapsid Protein of SARS-CoV-2 and Its Application to ELISA-Based Detection Methods with Broad Specificity by Combined Use of Detector Antibodies

Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization

Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2

Identification of SARS-CoV RBD-targeting Monoclonal Antibodies with Cross-Reactive or Neutralizing Activity Against SARS-CoV-2

Development of a double‐antibody sandwich ELISA for detection of SARS‐CoV‐2 variants based on nucleocapsid protein‐specific antibodies

A Monoclonal Antibody That Neutralizes SARS-CoV-2 Variants, SARS-CoV, and Other Sarbecoviruses

Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis.

Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies

Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5

Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2

A panel of multivalent nanobodies broadly neutralizing Omicron subvariants and recombinant

Distinct In Vitro and In Vivo Neutralization Profiles of Monoclonal Antibodies Elicited by the Receptor Binding Domain of the Ancestral SARS‐CoV‐2

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics

Preparation of highly specific monoclonal antibodies against SARS‐CoV‐2 nucleocapsid protein and the preliminary development of antigen detection test strips